Drug intelligence / Profile preview

GLIX5

Development stage: Preclinical
Lead developer: Hemispherian
Modality: Small Molecules

Overview

GLIX5 is a small molecule drug developed by Hemispherian AS, targeting the ten-eleven translocation oncogene 2 (TET2) enzyme. It acts as a TET2 protein stimulant and is being investigated for its potential in cancer therapy, specifically for glioblastoma and ovarian cancer. The mechanism of action involves epigenetic modulation through activation of the DNA damage response, leading to cancer cell death[1][6][8]. As of early 2025, GLIX5 remains in preclinical development.

Other names: GLIX-5GLIX5GLIX 5

Targets

TET2 (Methylcytosine dioxygenase TET2)

Beyond the preview

Go deeper on GLIX5.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GLIX5.

Explore the full profile